Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | ATM | Q13315 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | RAB9A | P51151 | 2/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | SGMS2 | Q8NHU3 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1684203 | 0.91 | POLB (0.40) | KMT2ARAB9AMAPK1MEN1ALDH1A1 | |
| SCHEMBL4912177 | 0.89 | SGMS2 (0.42) | ATMRAB9ASGMS2ALDH1A1NPC1 | |
| SCHEMBL4911188 | 0.87 | ELANE (0.40) | MAPTATMKMT2ARAB9AMAPK1 | |
| SCHEMBL4913829 | 0.85 | TUBB4A (0.37) | MAPT | |
| SCHEMBL4910413 | 0.79 | ROCK2 (0.35) | MAPTKMT2AMAPK1MEN1ALDH1A1 | |
| SCHEMBL4910742 | 0.78 | ELANE (0.41) | MAPTRAB9AALDH1A1NPC1POLB | |
| SCHEMBL4908541 | 0.71 | MAPT (0.43) | MAPTALDH1A1NPC1POLB | |
| SCHEMBL2951342 | 0.70 | MAPT (0.46) | MAPTATMKMT2ARAB9AMAPK1 | |
| SCHEMBL4915085 | 0.70 | MAPT (0.42) | MAPTATMKMT2ARAB9AMAPK1 | |
| SCHEMBL1608380 | 0.62 | GRIN2B (0.44) | RAB9ANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080221154-A1 | HIV-INTEGRASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND METHODS FOR THEIR USE | PFIZER INC | 2008-09-11 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080221154-A1 | HIV-INTEGRASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND METHODS FOR THEIR USE | TYMP, IMPDH1, POLB | MAPT 1998/4885ATM 2620/4885KMT2A 756/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.